Susan Wojcicki, a non-smoker and CEO of YouTube, was diagnosed with non-small cell lung cancer in 2022 at the age of 56. She ...

In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival ...

Tumor cells transform fibroblasts into cancer-associated fibroblasts, which have an important immunosuppressive activity on which growth, invasion, and metastasis depend. These activated fibroblasts ...

When Ed O. went to the ER for shortness of breath and trembling, he never imagined he’d receive a diagnosis of unresectable ...

Cancer continues to be one of the most challenging diseases to treat worldwide. The three main methods used to treat cancer are surgical excision, chemotherapy, and radiation therapy. Immunotherapy ...

With targeted treatment and a strong support group, she now lives a full life and serves the community that had her back.

Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...

In 2022, the Swiss pharma giant said SKYSCRAPER-01 failed to reach the co-primary goal of progression-free survival. The ...

Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in ...

Patients were administered the drugs every three weeks until disease progression, loss of clinical benefit or unacceptable ...

Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists ...